Las Vegas, NV -- (SBWIRE) -- 12/18/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: North American Palladium Ltd (USA) (NYSEMKT:PAL), Solta Medical Inc (NASDAQ:SLTM), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), Targacept , Inc.(NASDAQ:TRGT)
North American Palladium Ltd (USA) (NYSEMKT:PAL) managed to keep its fall at -7.26% on above-normal volume of 5.53M shares. The stock settled at $0.420 after floating in a range of $0.42 to $0.48. Its latest price has reached market capitalization of $82.65 million. Its 52-week range has been $0.37 to $1.98. Weyerhaeuser Company, a forest products company, grows and harvests trees, builds homes, and manufactures forest products worldwide. It grows and harvests trees for use as lumber, other wood and building products, and pulp and paper.
Has PAL Found The Bottom and Ready To Move Up? Find Out Here
Solta Medical Inc (NASDAQ:SLTM) traded up on a volume of 4.73 million, higher than its standard daily volume. Shares have gained 0.68% to $2.94. Over the last twelve months, the stock has gained 6.91% and faced a worst price of $1.44. Solta Medical, Inc. designs, develops, manufactures and markets professional and consumer energy-based medical device systems for aesthetic applications. The Company's systems are cleared by the United States Food and Drug Administration (FDA) for dermatological procedures performed in the physician led, professional assist, and personal care markets.
For How Long SLTM’s Gloss will Attract Investors? Find out via this report
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) settled -6.80% lower at $0.841 on above-normal volume of 4.76M shares during the last trading day. The stock has its 12-month high at $4 and 52-week low price was $0.81. It traded in a range of $0.81 to $0.84 during the last trading day. mmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.
Will IMUC Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Targacept , Inc.(NASDAQ:TRGT) was down on high volume, trading at a volume of 4.56M versus its average daily volume of 158,942.00 shares. At $3.91, the stock has attained market capitalization of 131.62 million. Targacept, Inc. is a biopharmaceutical company. The Company is engaged in the design, discovery and development of NNR Therapeutics for the treatment of diseases and disorders of the nervous system.
Why Should Investors Buy TRGT After the Recent Fall? Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)